This Article Full Text Full Text (PDF) An erratum has been published Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kamai, Y. Articles by Kuwahara, S. Search for Related Content PubMed PubMed Citation Articles by Kamai, Y. Articles by Kuwahara, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2005, p. 52-56, Vol. 49, No. 1
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.1.52-56.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Antifungal Activities of R-135853, a Sordarin Derivative, in Experimental Candidiasis in Mice

Biological Research Laboratories,¹ Drug Metabolism and Pharmacokinetics Research Laboratories, Sankyo Co., Ltd., Shinagawa-ku,² Toho University School of Medicine, Ohta-ku, Tokyo, Japan³

Received 10 June 2004/ Returned for modification 1 August 2004/ Accepted 8 September 2004

The activities of R-135853, a novel sordarin derivative that possesses a 1,4-oxazepane ring moiety, were evaluated in vitro and in vivo. R-135853 exhibited potent in vitro activities against Candida albicans (fluconazole-susceptible strains), Candida glabrata, Candida tropicalis, and Cryptococcus neoformans, with MICs at which 90% of isolates were inhibited of 0.03, 1, 0.5, and 0.5 µg/ml, respectively. R-135853 also exhibited potent activities against fluconazole-susceptible dose-dependent and fluconazole-resistant strains of C. albicans, with MICs ranging from 0.03 to 0.06 µg/ml. However, R-135853 exhibited weak or no activity against Candida parapsilosis, Candida krusei, and Aspergillus spp. R-135853 exhibited dose-dependent efficacy against experimental murine hematogenous candidiasis induced by C. albicans when it was administered by both the subcutaneous and the oral routes and reduced viable cell counts in the kidneys significantly when it was administered at 50 mg/kg of body weight/dose (administration three times a day). In this model, R-135853 also exhibited dose-dependent efficacy by single oral administration. Subcutaneous administration of R-135853 exhibited dose-dependent efficacy against experimental murine esophageal candidiasis induced by fluconazole-resistant C. albicans, against which fluconazole at 50 mg/kg/dose was ineffective, and reduced viable cell counts in the esophagus significantly when it was administered at 10 and 50 mg/kg/dose. R-135853 eradicated C. albicans from the esophagi of one and four of five mice when it was administered at 10 and 50 mg/kg/dose, respectively. These results suggest that R-135853 is promising for the treatment of disseminated or mucosal candidiasis, including fluconazole-refractory infections.